title: (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
abstract: OBJECTIVE
  Approximately 85% of patients with cancer suffer severe metastatic bone pain for which radionuclide therapy has been employed for pain palliation. We undertook this study to evaluate the pain relief effect of (153)Sm-EDTMP in Mexican patients with severe and painful bone metastases from mainly prostate, breast, and renal cancer and other malignancies.
  
  
  METHODS
  Patients (277) with intense sustained pain caused by bone metastases were referred to the Nuclear Medicine Department of the Oncology Hospital of the Mexican Social Security Institute. The patients had to have acceptable physical conditions, a previous positive (99m)Tc-MDP scan and blood values within normal range. (153)Sm-EDTMP was prepared at the Instituto Nacional de Investigaciones Nucleares (ININ) and 37 MBq/kg of body weight was injected intravenously. Pain palliation was evaluated with a visual analogue scale (VAS) and a verbal rating scale (VRS) before treatment and 3 and 12 weeks after treatment was started.
  
  
  RESULTS
  The age interval of the patients was 24-92 years with a mean age of 64 ± 12 years. Mean values for hemoglobin, leukocyte and platelet counts did not statistically differ at zero time, 3 and 12 weeks after treatment. Pain intensity and relief assessment were statistically different: 9.1 ± 0.61 units initially; 4.2 ± 1.3 units 3 weeks later (54%) and after 12 weeks the pain diminished to 2.4 ± 1.4 units (74%) in the pain relief score scales.
  
  
  CONCLUSIONS
  (153)Sm-EDTMP was readily available, safe and well tolerated. We conclude that (153)Sm-EDTMP was an adequate palliative agent and was the best option for our Mexican patients to relieve their severe metastatic bone pain.
authors.affiliation: Unidad Médica de Alta Especialidad "Hospital de Oncología" Siglo XXI, Instituto Mexicano de Seguro Social, México, D.F., Mexico.
authors.forename: Luis
authors.initials: L
authors.lastname: Correa-González
authors.affiliation: Nuclear Medicine Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., Mexico. Electronic address: camurphy53@yahoo.com.mx.
authors.forename: Consuelo
authors.initials: C
authors.lastname: Arteaga de Murphy
authors.affiliation: Unidad Médica de Alta Especialidad "Hospital de Oncología" Siglo XXI, Instituto Mexicano de Seguro Social, México, D.F., Mexico.
authors.forename: Pablo
authors.initials: P
authors.lastname: Pichardo-Romero
authors.affiliation: Nuclear Medicine Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., Mexico.
authors.forename: Martha
authors.initials: M
authors.lastname: Pedraza-López
authors.affiliation: Unidad Médica de Alta Especialidad "Hospital de Oncología" Siglo XXI, Instituto Mexicano de Seguro Social, México, D.F., Mexico.
authors.forename: Claudia
authors.initials: C
authors.lastname: Moreno-García
authors.affiliation: Ciclotrónica Mexicana, Morelos, Mexico.
authors.forename: Luis
authors.initials: L
authors.lastname: Correa-Hernández
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018712:Analgesics, Non-Narcotic / Q000493:pharmacokinetics / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D003110:Colonic Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010146:Pain / Q000000981:diagnostic imaging / Q000209:etiology / Q000532:radiotherapy*; D010147:Pain Measurement; D010166:Palliative Care / Q000379:methods; D011471:Prostatic Neoplasms / Q000473:pathology*; D011788:Quality of Life; D011877:Radionuclide Imaging; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam
keywords: (153)Sm-EDTMP; Bone metastases; Breast cancer; Pain relief; Prostate cancer